# US 2025/0084098 A1 · Fused-ring amine derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084098 A1
- Document ID: US20250084098A1
- Status: Published application
- Kind: A1
- Application number: 18/292,585
- Filed: 2022-07-27
- Published: 2025-03-13
- Earliest claimed: 2021-07-28
- Assignees: Sumitomo Pharma Co., Ltd.; Carna Biosciences, Inc.
- Applicants: Sumitomo Pharma Co., Ltd.; Carna Biosciences, Inc.
- Inventors: Shingo TOJO; Daisuke URABE; Hitoshi WATANABE
- Web page: https://patentgrep.com/patent/US20250084098A1

## CPC

- C07D 513/04: Ortho-condensed systems
- A61K 31/428: condensed with carbocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 7/06: Antianaemics
- A61P 13/12: of the kidneys
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a fused-ring amine derivative that has a DYRK inhibitory effect and that is represented by formula (1) (refer to the description with respect to A1, L1, T, Z and l in the formula), or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A compound represented by:
wherein
A1 represents optionally substituted methylene or an oxygen atom,
L1 represents optionally substituted methylene or optionally substituted ethylene,
1 represents 1, 2, or 3,
T represents a hydrogen atom or optionally substituted C1-6 alkyl,
Z represents —NR1R2 or —OR3,
R1 and R2 each independently represent a hydrogen atom, optionally substituted C1-6 alkyl, or
C(O)—RA, or R1 and R2, together with the nitrogen atom to which they are attached, may form an optionally substituted 4- to 7-membered saturated heterocycle,
RA represents —RA1 or —ORA1,
RA1 represents optionally substituted C1-6 alkyl,
R3 represents a hydrogen atom, optionally substituted C1-6 alkyl, or C(O)—RB, and
RB represents optionally substituted C1-6 alkyl,
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein A1 is methylene, and L1 is optionally substituted methylene or optionally substituted ethylene.

### Claim 3 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein A1 is an oxygen atom, and L1 is optionally substituted methylene or optionally substituted ethylene.

### Claim 4 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein 1 is 1 or 2.

### Claim 5 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Z is —NR1R2.

### Claim 6 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Z is —OR3.

### Claim 7 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 and R2 each independently are a hydrogen atom or optionally substituted C1-6 alkyl.

### Claim 8 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 and R2, together with the nitrogen atom to which they are attached, form an optionally substituted 4- to 7-membered saturated heterocycle.

### Claim 9 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R3 is a hydrogen atom or optionally substituted C1-6 alkyl.

### Claim 10 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein T is methyl optionally substituted with a halogen atom.

### Claim 11 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group of the following compounds:
(3aR,4R,6aR)-1-(7,8-dihydrofuro[3,2-e][1,3]benzothiazol 2-yl)-2-oxooctahydrocyclopenta[d]imidazol 4-yl rac-acetate (Example 6);
(3aR,4R,6aR)-3-(7,8-dihydrofuro[3,2-e][1,3]benzothiazol 2-yl)-2-oxooctahydrocyclopenta[d]imidazol 4-yl rac-acetate (Example 7);
rac-(3aR,6R,6aR)-1-(7,8-dihydrofuro[3,2-e][1,3]benzothiazol 2-yl)-6-hydroxyhexahydrocyclopenta[d]imidazol 2(1H)-one (Example 10);
rac-(3aR,4R,6aR)-1-(7,8-dihydrofuro[3,2-e][1,3]benzothiazol 2-yl)-4-hydroxyhexahydrocyclopenta[d]imidazol 2(1H)-one (Example 11);
rac-(3aR,4S,6aS)-1-(7,8-dihydrofuro[3,2-e][1,3]benzothiazol 2-yl)-4-(methylamino)hexahydrocyclopenta[d]imidazol 2(1H)-one (Example 14);
rac-(3aR,4S,6aS)-1-(7,8-dihydrofuro[3,2-e][1,3]benzothiazol 2-yl)-4-(dimethylamino)hexahydrocyclopenta[d]imidazol 2(1H)-one (Example 19);
rac-{[(3aR,4S,6aS)-1-(7,8-dihydrofuro[3,2-e][1,3]benzothiazol 2-yl)-2-oxooctahydrocyclopenta[d]imidazol 4-yl](methyl)amino}acetonitrile (Example 20);
rac-(3aR,6R,6aR)-1-(7,8-dihydrofuro[3,2-e][1,3]benzothiazol 2-yl)-6-(dimethylamino)hexahydrocyclopenta[d]imidazol 2(1H)-one (Example 21);
rac-{[(4R)-3-(7,8-dihydrofuro[3,2-e][1,3]benzothiazol 2-yl)-2-oxooctahydrocyclopenta[d]imidazol 4-yl](methyl)amino}acetonitrile (Example 22);
rac-{[(3aR,5R,6aS)-1-(7,8-dihydrofuro[3,2-e][1,3]benzothiazol 2-yl)-2-oxooctahydrocyclopenta[d]imidazol 5-yl](methyl)amino}acetonitrile (Example 30);
rac-{[(3aR,5R,6aS)-1-(7,8-dihydrofuro[3,2-e][1,3]benzothiazol 2-yl)-2-oxooctahydrocyclopenta[d]imidazol 5-yl]amino}acetonitrile (Example 31);
rac-(3aR,6R,6aR)-6-(3,3-difluoroazetidin-1-yl)-1-(7,8-dihydrofuro[3,2-e][1,3]benzothiazol 2-yl)hexahydrocyclopenta[d]imidazol 2(1H)-one (Example 34);
(3aS,4R,6aR)-4-amino-1-(7,8-dihydrofuro[3,2-e][1,3]benzothiazol 2-yl)hexahydrocyclopenta[d]imidazol 2(1H)-one (Example 37);
(3aS,4R,6aR)-4-(cyclopropylamino)-1-(7,8-dihydrofuro[3,2-e][1,3]benzothiazol-2-yl)hexahydrocyclopenta[d]imidazol 2(1H)-one (Example 40);
rac-(3aR,4S,6aS)-4-(3,3-difluoroazetidin-1-yl)-1-(7,8-dihydrofuro[3,2-e][1,3]benzothiazol-2-yl)hexahydrocyclopenta[d]imidazol-2(1H)-one (Example 45);
rac-(3aR,6R,6aS)-6-(cyclopropylamino)-1-(7,8-dihydrofuro[3,2-e][1,3]benzothiazol-2-yl)hexahydrocyclopenta[d]imidazol-2(1H)-one (Example 46);
rac-(3aR,6R,6aR)-1-(7,8-dihydrofuro[3,2-e][1,3]benzothiazol-2-yl)-6-(morpholin-4-yl)hexahydrocyclopenta[d]imidazol-2(1H)-one (Example 47);
rac-(3aR,6R,6aR)-6-[cyclopropyl(methyl)amino]-1-(7,8-dihydrofuro[3,2-e][1,3]benzothiazol-2-yl)hexahydrocyclopenta[d]imidazol-2(1H)-one (Example 49);
(3aS,6S,6aS)-1-(7,8-dihydrofuro[3,2-e][1,3]benzothiazol-2-yl)-6-(dimethylamino)hexahydrocyclopenta[d]imidazol-2(1H)-one (Example 50);
(3aR,4R,5S,6aR)-1-(7,8-dihydrofuro[3,2-e][1,3]benzothiazol-2-yl)-4-(dimethylamino)-5-methylhexahydrocyclopenta[d]imidazol-2(1H)-one (Example 57);
(3aR,4R,5S,6aR)-1-(7,8-dihydrofuro[3,2-e][1,3]benzothiazol-2-yl)-4-(dimethylamino)-5-(fluoromethyl)hexahydrocyclopenta[d]imidazol-2(1H)-one (Example 58);
(3aR,4R,5S,6aR)-4-(dimethylamino)-1-(2H-[1,3]dioxolo[4,5-e][1,3]benzothiazol-7-yl)-5-methylhexahydrocyclopenta[d]imidazol-2(1H)-one (Example 59); and
(3aR,4R,5S,6aR)-4-(dimethylamino)-1-(2H-[1,3]dioxolo[4,5-e][1,3]benzothiazol-7-yl)-5-(fluoromethyl)hexahydrocyclopenta[d]imidazol-2(1H)-one (Example 60).

### Claim 12 (depends on 1)

A medicament comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

### Claim 14 (depends on 1)

A therapeutic agent and/or a prophylactic agent for a disease involving DYRK, comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

### Claim 15 (depends on 14)

The therapeutic agent and/or the prophylactic agent according to claim 14, wherein the disease involving DYRK is frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration, Lewy body dementia, vascular dementia, traumatic brain injury, chronic traumatic encephalopathy, stroke, Alzheimer's disease, Parkinson's disease, Down's syndrome, or depression, and mental retardation, memory impairment, memory loss, learning disability, intellectual disability, cognitive dysfunction, mild cognitive impairment, or dementia symptom associated therewith, or brain tumor, pancreatic cancer, ovarian cancer, osteosarcoma, colorectal cancer, lung cancer, bone resorption disease, osteoporosis, sickle cell anemia, chronic renal disease, or bone resorption disease.

### Claim 16 (depends on 1)

A method for treating and/or preventing a disease involving DYRK, comprising administration of a therapeutically effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof to a patient in need of treatment.

### Claim 17 (depends on 1)

Use of the compound according to claim 1 or a pharmaceutically acceptable salt thereof, for producing a therapeutic agent and/or a prophylactic agent for a disease involving DYRK.

### Claim 18 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, for use in treatment and/or prevention of a disease involving DYRK.

### Claim 19 (depends on 12)

A medicament obtained by combining the medicament according to claim 12 and at least one or more agents selected from agents classified into an anticancer agent, an antipsychotic drug, an antidementia drug, an antiepileptic drug, an antidepressant drug, a gastrointestinal drug, a thyroid hormone drug, or an antithyroid drug.

### Claim 20 (depends on 12)

The medicament according to claim 12, for treating frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration, Levy body dementia, vascular dementia, traumatic brain injury, chronic traumatic encephalopathy, stroke, Alzheimer's disease, Parkinson's disease, Down's syndrome, or depression, and complication, mental retardation, memory impairment, memory loss, learning disability, intellectual disability, cognitive dysfunction, mild cognitive impairment, or treating dementia symptom progression or preventing dementia onset associated therewith, or treating brain tumor, pancreatic cancer, ovarian cancer, osteosarcoma, colorectal cancer, lung cancer, bone resorption disease, osteoporosis, sickle cell anemia, chronic renal disease, or bone resorption disease, in combination with at least one or more agents selected from agents classified into an anticancer agent, an antipsychotic drug, an antidementia drug, an antiepileptic drug, an antidepressant drug, a gastrointestinal drug, a thyroid hormone drug, or an antithyroid drug.
